Swamy Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-06-2024
- Paid Up Capital ₹ 0.10 M
as on 21-06-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2020)
- Profit -29.53%
(FY 2020)
- Ebitda -117.28%
(FY 2020)
- Net Worth -30.63%
(FY 2020)
- Total Assets -10.18%
(FY 2020)
About Swamy Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chandra Yelgapuri, Krishnaveni Yelgapuri, Swamy Yelgapuri, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232TG2011PTC076393
- Company No.
076393
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Swamy Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandra Yelgapuri  | Director | 08-Sep-2011 | Current |
| Krishnaveni Yelgapuri | Director | 08-Sep-2011 | Current |
| Swamy Yelgapuri | Director | 08-Sep-2011 | Current |
| Ram Yelgapuri | Director | 08-Sep-2011 | Current |
Financial Performance of Swamy Pharma.
Swamy Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 29.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 30.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swamy Pharma?
In 2019, Swamy Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rr Veterinary Health Care Private LimitedActive 8 years 6 monthsKrishnaveni Yelgapuri and Ram Yelgapuri are mutual person
Sujana Life Sciences Private LimitedActive 8 years 11 monthsKrishnaveni Yelgapuri and Ram Yelgapuri are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Swamy Pharma?
Unlock and access historical data on people associated with Swamy Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swamy Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swamy Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
